{
  "report_rows": [
    {
      "kpi": "Q2 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.585B vs. cons $1.560B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$7.78 vs. cons $7.64",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 segment margin",
      "prediction": "BEAT",
      "answer": "pred ~23.1% vs. cons 22.8%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EPS guidance midpoint",
      "prediction": "LOWER",
      "answer": "guide ~$24.25 vs. cons $24.43 (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY2026 revenue growth guidance",
      "prediction": "LOWER",
      "answer": "guide ~8.0% vs. cons 8.1% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 free cash flow guidance midpoint",
      "prediction": "LOWER",
      "answer": "guide ~$800M vs. cons $805M (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.8,
  "day5_path": "FADE",
  "day5_rationale": "Day-5 residual ~+1.8% vs. day-1 residual +3.2%: a Q2 beat and improving HCS absorption support the initial gain, but unchanged FY2026 guidance with its ~$24.25 midpoint below the $24.43 consensus limits estimate revisions as tariff and price-cost pressure shifts into Q3 and Q4.",
  "day5_confidence": "MEDIUM"
}